Navigation Links
A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy
Date:3/5/2008

. Blasticon's therapeutic agents are for the most part in advanced stages of preclinical or clinical phases of development. In most cases, the medical fields of application described necessitate costly lifelong treatment. Blasticon's reprogrammed cells make it possible to attack illnesses at their origin and to prevent long duration of treatment. A further possible positive effect of the technologies is significant cost-reduction in the health system.

Products which are ready for application and soon to be introduced onto the market

The diagnostic application of the in vitro acute toxicity test "NeoHeps" can be introduced onto the market as soon as NeoHelps has been successfully validated by the European Union (EU). The REACH programme, a new EU chemical regulation that came into force on 1 June 2007 is of particular importance here; it will in future oblige all manufacturers, importers and users of chemicals to evaluate their substances as being safe. This presents a great challenge to many industries, whether they produce shampoos, kitchen utensils, computers, televisions, furniture or clothing - owing to the implementation of REACH, over 30,000 known chemicals are to be retested for their toxic safety. New chemical entities must also be tested with the REACH test regime. According to estimates, around 3,500 tests a year will be necessary.

Up to now, Blasticon's "NeoHeps" test system has passed all necessary tests within the EU test framework and has therefore been able to secure itself a clear market lead. In addition, "NeoHeps" could be of considerable benefit to the pharmaceutical industry, for example in examining the effectiveness and undesirable side effects of medicines. The advantages are less animal testing, unlimited availability of the required cells and cost-reduction in the area of drug development.

Prof. Dr. med Fandrich comments on the current political debate: "Personally, I do not think much of the use of embryonic cell
'/>"/>

SOURCE Blasticon Biotechnologische Forschung GmbH
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Germany Hosts World Leading Medical Industry Fair
2. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
3. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
4. ROBODOC(R) Emerges as a Curexo Technology Company at Upcoming Orthopaedic Surgeons Conference in San Francisco
5. Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations
6. National Stem Cell Holding, Inc. Has Engaged BMA Securities to Assist and Advise the Company With Its Current Capital Raise of $3,500,000
7. European Company NovaSecta Joins First Chinese CRO Service Alliance for Drug Discovery Solutions
8. Nastech Pharmaceutical Company Implements Additional Workforce Reduction as Part of Previously Announced Corporate Restructuring
9. Halogen Announces Record Year - Company Solidifies Leadership Position, Secures Strategic Wins Over Competition
10. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
11. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... 03, 2015 Becht Engineering Co., ... it has acquired The CECON Group, Inc., located ... were not announced. , Becht Engineering (http://www.becht.com ... sector including oil and gas production, refining, petrochemical, ... nuclear power sectors. The company has twelve offices ...
(Date:3/3/2015)... Research and Markets ( http://www.researchandmarkets.com/research/s3s3t8/personalized ... new report "Personalized Medicine - Scientific and ... The aim of personalized medicine or ... to the right patient and, in some cases, ... patient according to his/her genotype. This report describes ...
(Date:3/3/2015)... 2015  Johnson & Johnson Innovation LLC today announced ... (JLABS @SSF), a 30,000-square foot incubator located ... Francisco, Calif. The Johnson & Johnson Innovation, ... from across the healthcare spectrum including biotech, pharmaceutical, medical ... first resident startups have been selected, including the winners ...
(Date:3/3/2015)... , March 3, 2015  Synthetic Biologics, Inc. (NYSE ... and diseases, with a focus on protecting the microbiome, announced ... scheduled to present at the 27th Annual ROTH Conference being ... Laguna Niguel in Dana Point, CA. ... March 10, 2015 at 1:00 p.m. (Pacific Time). ...
Breaking Biology Technology:Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 2Global Personalized Medicine Market Report 2015 - Scientific and Commercial Aspects 2014-2024 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 2Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 3Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 4Johnson & Johnson Innovation Opens JLABS @South San Francisco and Announces First Five Resident Startups 5Synthetic Biologics to Present at the 27th Annual ROTH Conference 2
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) announced today that ... Second Annual Hidden Gems Conference on October,13, 2008 at ... the,Waldorf=Astoria Hotel in New York City. Robert E. Hoffman, ... to provide an,overview of the company, including its clinical ...
... 7 Nektar,Therapeutics (Nasdaq: NKTR ) President and ... upcoming Natixis Bleichroeder Second Annual Hidden Gems,Conference in New ... at 2:30 p.m. ET., The presentation will be ... Relations, Events Calendar section of the Nektar website:, http://www.nektar.com ...
... 7 MKS Instruments, Inc.,(Nasdaq: MKSI ), ... and improve productivity, today announced that it will ... opening on Wednesday,October 22, 2008. A conference call ... 8:30 a.m. (Eastern Time). The call will be ...
Cached Biology Technology:Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference 3
(Date:2/18/2015)... Feb. 18, 2015  Cepheid (NASDAQ: CPHD ) ... following conferences, and invited investors to participate via webcast. ... MA Tuesday, March 3, 2015 at 11.20 a.m. ... Orlando, FL Wednesday, March 4, 2015 at ... access the live webcasts for these events, please visit Cepheid,s ...
(Date:2/12/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... authentication company focused on the growing mobile commerce market, ... for DISTRIBUTED METHOD AND SYSTEM TO IMPROVE ... further establishes NXT-ID,s position in the emerging "Internet of ... ability for multiple devices to collaborate with one another ...
(Date:2/9/2015)... Texas , Feb. 9, 2015  Lintec of ... fabrication methods for carbon nanotube (CNT) macrostructures, including sheets, ... at Dallas (UTD). Leveraging the vast industrial ... Tokyo, Japan , Lintec of America is ... Richardson, TX , focusing on scaling up ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... researchers from the British Antarctic Survey have collected individuals from ... and subjected them to increasing levels of water temperature to ... conditions that they are likely to experience in the future. ... living really close to their upper temperature range, and that ...
... A University of Wisconsin-Madison biomedical engineer and colleagues have developed ... could spare some women with increased breast cancer risk the ... a questionable lump or lesion. The universal technology will ... malignant or benign. The American Cancer Society recommends ...
... an effort to increase understanding of the medical device ... of product development more effectively, researchers at Stanford University ... device development process. Published in the June ... , the model was constructed based on best-practice analysis ...
Cached Biology News:New MRI technique could mean fewer breast biopsies in high-risk women 2Stanford researchers publish comprehensive model for medical device development 2Stanford researchers publish comprehensive model for medical device development 3
Phospho-TAO2 (S181) Affinity Purified Polyclonal Ab Protein Family: Other Intracellular Kinases...
PEG 8000, Molecular Biology Grade...
... Histone Deacetylase (HDAC) Antibody Sampler Kit ... (HDAC1) Antibody, Catalog #2062, 40 ul Histone ... ul Histone Deacetylase 4 (HDAC4) Antibody, Catalog ... Antibody, Catalog #2082, 40 ul Histone Deacetylase ...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: